Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of the Biosimilar Natalizumab PB006 in Comparison to Tysabri®

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female patients (age ≥18 to 60 years), with relapsing-remitting multiple sclerosis (RRMS) defined by the 2010 revised McDonald criteria~* At least 1 documented relapse within the previous year and either ≥1 GdE T1-weighted brain lesions or ≥9 T2-weighted brain lesions at Screening~* Kurtzke Expanded Disability Status Scale (EDSS) score from 0 to 5 (inclusive) at Screening~Exclusion Criteria:~* Manifestation of multiple sclerosis (MS) other than relapsing-remitting multiple sclerosis (RRMS)~* Relapse within the 30 days prior Screening and until administration of the first dose of study drug~* Prior treatment with natalizumab, alemtuzumab, ocrelizumab, daclizumab, rituximab, cladribine, or other B- and T-cell targeting therapies~* Prior total lymphoid irradiation or bone marrow or organ transplantation~* Patients with John Cunningham Virus (JCV) index \>1.5 at Screening~* Past or current Progressive Multi-focal leukoencephalopathy (PML) diagnosis~* Severe renal function impairment as defined by serum creatinine values \>120 micromol per litre

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- PB006 (Type: EXPERIMENTAL): Patients with relapsing-remitting multiple sclerosis (RRMS) received intravenous (IV) infusions every 4 weeks of PB006 at a dose of 300 milligram (mg) starting at Visit 1 (Week 0) through Visit 12 (Week 44), for a total of 12 infusions.
- Tysabri (Type: ACTIVE_COMPARATOR): Patients with relapsing-remitting multiple sclerosis (RRMS) received intravenous (IV) infusions every 4 weeks of Tysabri at a dose of 300 milligram (mg) starting at Visit 1 (Week 0) through Visit 12 (Week 44), for a total of 12 infusions. At Week 24, patients in the Tysabri group were re-randomized through a re-randomization step. Patients re-randomized and switched from Tysabri to PB006 at Week 24 still received a total of 12 infusions (6 infusions of Tysabri and 6 infusions of PB006).

Based on this trial design, predict the completion outcome and termination type (if applicable).